Syracuse Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
1
Syracuse General Information
Description
Developer of clinical-stage biopharmaceuticals designed for the treatment of solid tumor cancers. The company offers T-cell immunotherapies based on the proprietary Artemis technology platform, thereby providing patients in China and ASEAN countries with advanced treatments for hepatocellular carcinoma and other solid tumors to enhance clinical outcomes and therapeutic precision.
Contact Information
(Operating Subsidiary)
Corporate Office
- St George's Building
- Central
- Hong Kong
- Hong Kong
Corporate Office
- St George's Building
- Central
- Hong Kong
- Hong Kong
Syracuse Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Syracuse Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Syracuse Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Syracuse FAQs
-
When was Syracuse founded?
Syracuse was founded in 2018.
-
Where is Syracuse headquartered?
Syracuse is headquartered in Hong Kong, Hong Kong.
-
What industry is Syracuse in?
Syracuse’s primary industry is Drug Discovery.
-
Is Syracuse a private or public company?
Syracuse is a Private company.
-
What is Syracuse’s current revenue?
The current revenue for Syracuse is .
-
Who are Syracuse’s investors?
Eureka Therapeutics has invested in Syracuse.
-
When was Syracuse acquired?
Syracuse was acquired on 20-Jul-2020.
-
Who acquired Syracuse?
Syracuse was acquired by JW Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
